Top

Published in:

01-04-2013 | Original article

Inhibition of both BRAF and MEK in BRAF^V600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties

Authors: Patrick A. Ott, Trevor Henry, Sonja Jimenez Baranda, Davor Frleta, Olivier Manches, Dusan Bogunovic, Nina Bhardwaj

Published in: Cancer Immunology, Immunotherapy | Issue 4/2013

Abstract

Purpose

Dendritic cells (DCs) can induce strong tumor-specific T-cell immune responses. Constitutive upregulation of the mitogen-activated protein kinase (MAPK) pathway by a BRAF^V600 mutation, which is present in about 50 % of metastatic melanomas, may be linked to compromised function of DCs in the tumor microenvironment. Targeting both MEK and BRAF has shown efficacy in BRAF^V600 mutant melanoma.

Methods

We co-cultured monocyte-derived human DCs with melanoma cell lines pretreated with the MEK inhibitor U0126 or the BRAF inhibitor vemurafenib. Cytokine production (IL-12 and TNF-α) and surface marker expression (CD80, CD83, and CD86) in DCs matured with the Toll-like receptor 3/Melanoma Differentiation-Associated protein 5 agonist polyI:C was examined. Additionally, DC function, viability, and T-cell priming capacity were assessed upon direct exposure to U0126 and vemurafenib.

Results

Cytokine production and co-stimulation marker expression were suppressed in polyI:C-matured DCs exposed to melanoma cells in co-cultures. This suppression was reversed by MAPK blockade with U0126 and/or vemurafenib only in melanoma cell lines carrying a BRAF^V600E mutation. Furthermore, when testing the effect of U0126 directly on DCs, marked inhibition of function, viability, and DC priming capacity was observed. In contrast, vemurafenib had no effect on DC function across a wide range of dose concentrations.

Conclusions

BRAF^V600E mutant melanoma cells modulate DC through the MAPK pathway as its blockade can reverse suppression of DC function. MEK inhibition negatively impacts DC function and viability if applied directly. In contrast, vemurafenib does not have detrimental effects on important functions of DCs and may therefore be a superior candidate for combination immunotherapy approaches in melanoma patients.

Available only for authorised users

Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516. doi:10.1056/NEJMoa1103782 PubMedCrossRef

Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809–819. doi:10.1056/NEJMoa1002011 PubMedCrossRef

Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707–714. doi:10.1056/NEJMoa1112302 PubMedCrossRef

Flaherty KT, Infante JR, Daud A et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. doi:10.1056/NEJMoa1210093

Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. doi:10.1056/NEJMoa1203421

Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723. doi:10.1056/NEJMoa1003466 PubMedCrossRef

Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526. doi:10.1056/NEJMoa1104621 PubMedCrossRef

Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465. doi:10.1056/NEJMoa1200694 PubMedCrossRef

Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454. doi:10.1056/NEJMoa1200690 PubMedCrossRef

10.

Dudley ME, Yang JC, Sherry R et al (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233–5239. doi:10.1200/JCO.2008.16.5449 PubMedCrossRef

11.

Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263–274. doi:10.1038/nrc1586 PubMedCrossRef

12.

Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295–307PubMedCrossRef

13.

Yang Z–Z, Novak AJ, Stenson MJ, Witzig TE, Ansell SM (2006) Intratumoral CD4+ CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107:3639–3646PubMedCrossRef

14.

Viguier M, Lemaitre F, Verola O, Cho M-S, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L (2004) Foxp3 expressing CD4+ CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol (Baltimore, Md: 1950) 173:1444–1453

15.

Dong H, Chen L (2003) B7–H1 pathway and its role in the evasion of tumor immunity. J Mol Med 81:281–287PubMed

16.

Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027–1034PubMedCrossRef

17.

Wang T, Niu G, Kortylewski M et al (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48–54PubMedCrossRef

18.

Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41–51PubMedCrossRef

19.

Boni A, Cogdill AP, Dang P et al (2010) Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70:5213–5219. doi:10.1158/0008-5472.CAN-10-0118 PubMedCrossRef

20.

Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA (2012) Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18:1386–1394. doi:10.1158/1078-0432.CCR-11-2479 PubMedCrossRef

21.

Adams S, O’Neill DW, Bhardwaj N (2005) Recent advances in dendritic cell biology. J Clin Immunol 25:177–188PubMed

22.

Lee AW, Truong T, Bickham K, Fonteneau JF, Larsson M, Da Silva I, Somersan S, Thomas EK, Bhardwaj N (2002) A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 20(Suppl 4):A8–A22PubMedCrossRef

23.

Gorden A, Osman I, Gai W, He D, Huang W, Davidson A, Houghton AN, Busam K, Polsky D (2003) Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 63:3955–3957PubMed

24.

Sondergaard JN, Nazarian R, Wang Q et al (2010) Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific RAF inhibitor PLX4032. J Transl Med 8:39. doi:10.1186/1479-5876-8-39 PubMedCrossRef

25.

Smalley KS, Contractor R, Haass NK, Lee JT, Nathanson KL, Medina CA, Flaherty KT, Herlyn M (2007) Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Br J Cancer 96:445–449. doi:10.1038/sj.bjc.6603596 PubMedCrossRef

26.

Callahan M (2011) Defining the effects of MAPK pathway inhibition in human immune cells. Perspectives in Melanoma XV. Imedex, New York, NY

27.

Comin-Anduix B, Chodon T, Sazegar H et al (2010) The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res 16:6040–6048. doi:10.1158/1078-0432.CCR-10-1911 PubMedCrossRef

28.

Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107–114. doi:10.1056/NEJMoa1203421 PubMedCrossRef

29.

Sumimoto H, Imabayashi F, Iwata T, Kawakami Y (2006) The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203:1651–1656. doi:10.1084/jem.20051848 PubMedCrossRef

30.

Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma R, Thompson JF, Kefford RF, Hersey P, Scolyer RA (2011) Selective BRAF inhibitors induce marked T cell infiltration into human metastatic melanoma. Clin Cancer Res. doi:10.1158/1078-0432.CCR-11-2479 PubMed

31.

Vujanovic L, Ballard W, Thorne SH, Vujanovic NL, Butterfield LH (2012) Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10. Oncoimmunology 1:448–457PubMedCrossRef

32.

Jackson AM, Mulcahy LA, Zhu XW, O’Donnell D, Patel PM (2008) Tumour-mediated disruption of dendritic cell function: inhibiting the MEK1/2-p44/42 axis restores IL-12 production and Th1-generation. Int J Cancer 123:623–632. doi:10.1002/ijc.23530 PubMedCrossRef

33.

Bogunovic D, Manches O, Godefroy E, Yewdall A, Gallois A, Salazar AM, Marie I, Levy DE, Bhardwaj N (2011) TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res 71:5467–5476. doi:10.1158/0008-5472.CAN-10-3988 PubMedCrossRef

34.

Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA (2010) Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in BRAF-mutant human cutaneous melanoma cells. Cancer Res 70:8736–8747. doi:10.1158/0008-5472.CAN-10-0902 PubMedCrossRef

35.

VanBrocklin MW, Verhaegen M, Soengas MS, Holmen SL (2009) Mitogen-activated protein kinase inhibition induces translocation of BMF to promote apoptosis in melanoma. Cancer Res 69:1985–1994. doi:10.1158/0008-5472.CAN-08-3934 PubMedCrossRef

36.

Hong DS, Vence LM, Falchook GS et al (2012) Braf(V600) inhibitor Gsk2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res. doi:10.1158/1078-0432.CCR-11-2515

37.

Puig-Kroger A, Relloso M, Fernandez-Capetillo O, Zubiaga A, Silva A, Bernabeu C, Corbi AL (2001) Extracellular signal-regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells. Blood 98:2175–2182PubMedCrossRef

38.

Escors D, Lopes L, Lin R, Hiscott J, Akira S, Davis RJ, Collins MK (2008) Targeting dendritic cell signaling to regulate the response to immunization. Blood 111:3050–3061. doi:10.1182/blood-2007-11-122408 PubMedCrossRef

39.

Ardeshna KM, Pizzey AR, Devereux S, Khwaja A (2000) The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood 96:1039–1046PubMed

40.

Arrighi JF, Rebsamen M, Rousset F, Kindler V, Hauser C (2001) A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J Immunol 166:3837–3845PubMed

41.

Martinez D, Vermeulen M, von Euw E et al (2007) Extracellular acidosis triggers the maturation of human dendritic cells and the production of IL-12. J Immunol 179:1950–1959PubMed

42.

Yu Q, Kovacs C, Yue FY, Ostrowski MA (2004) The role of the p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and phosphoinositide-3-OH kinase signal transduction pathways in CD40 ligand-induced dendritic cell activation and expansion of virus-specific CD8+ T cell memory responses. J Immunol 172:6047–6056PubMed

43.

Oberholzer PA, Kee D, Dziunycz P et al (2012) RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 30:316–321. doi:10.1200/JCO.2011.36.7680 PubMedCrossRef

44.

Su F, Viros A, Milagre C et al (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207–215. doi:10.1056/NEJMoa1105358 PubMedCrossRef

45.

Hong DS, Vence L, Falchook G et al (2012) BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 18:2326–2335. doi:10.1158/1078-0432.CCR-11-2515 PubMedCrossRef

Title: Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties
Authors: Patrick A. Ott
Trevor Henry
Sonja Jimenez Baranda
Davor Frleta
Olivier Manches
Dusan Bogunovic
Nina Bhardwaj
Publication date: 01-04-2013
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 4/2013
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-012-1389-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2013

Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG

Functional human Th17 clones with WT1-specific helper activity

Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails

TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4+CD25+ Treg apoptosis

Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells

The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses

Keynote webinar | Spotlight on antibody–drug conjugates in cancer